Chuan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chuan Liu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Liang Gao
Department of Urology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
6 shared publicationsYa-Dong Li
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
6 shared publicationsHao Huang
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
5 shared publicationsWei Tan
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
5 shared publicationsYuan-Qing Gou
Department of Urology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
4 shared publicationsHao Wu
Department of Urology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
3 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1907524
Durable biochemical and radiographic response during toripalimab treatment in MSI-high/TMB-high mCRPC: a case report
We present a 79-year-old male patient with MSI-H/TMB-H (91.5 mutations/Mb) metastatic castration-resistant prostate cancer who progressed following abiraterone and enzalutamide treatment. When toripalimab was started, his serum PSA was 102 ng/mL. We maintained androgen-deprivation therapy with leuprorelin and stopped enzalutamide. Toripalimab 240 mg was given intravenously every 21 days. His PSA dropped below 0.09 ng/mL after three treatment cycles. We retrospectively applied RECIST version 1.1 criteria and selected the locally invasive prostate-soft-tissue mass as our only measurable non-nodal target lesion. Its maximal diameter shrank from 119 mm at baseline to 43 mm after six cycles (63.9% reduction), and further to 31 mm after 25 cycles (73.9% reduction), satisfying criteria for partial response. Pelvic lymph nodes could only be classified as non-target disease because short-axis diameters were unavailable in imaging reports, though these nodes resolved on imaging after six cycles. Bone lesions were not included in RECIST response evaluation and were interpreted separately on serial bone scans. At cycle 31 (roughly 21 months after toripalimab commencement), PSA stayed undetectable without clinical or radiological signs of progression; the biochemical response persisted for about 19 months starting from cycle 3. As of manuscript revision, the patient remains on toripalimab plus leuprorelin with routine follow-up. No treatment-related adverse events were identified using CTCAE version 5.0. We also conducted a targeted narrative review of mCRPC cases treated with PD-1/PD-L1 inhibitors other than pembrolizumab. This single-case observation highlights the value of genomic profiling for mCRPC patients with relevant biomarkers. Readers should interpret these findings as hypothesis-generating and not proof of universal toripalimab activity.
- 9 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1907524
Open AccessDurable biochemical and radiographic response during toripalimab treatment in MSI-high/TMB-high mCRPC: a case report
We present a 79-year-old male patient with MSI-H/TMB-H (91.5 mutations/Mb) metastatic castration-resistant prostate cancer who progressed following abiraterone and enzalutamide treatment. When toripalimab was started, his serum PSA was 102 ng/mL. We maintained androgen-deprivation therapy with leuprorelin and stopped enzalutamide. Toripalimab 240 mg was given intravenously every 21 days. His PSA dropped below 0.09 ng/mL after three treatment cycles. We retrospectively applied RECIST version 1.1 criteria and selected the locally invasive prostate-soft-tissue mass as our only measurable non-nodal target lesion. Its maximal diameter shrank from 119 mm at baseline to 43 mm after six cycles (63.9% reduction), and further to 31 mm after 25 cycles (73.9% reduction), satisfying criteria for partial response. Pelvic lymph nodes could only be classified as non-target disease because short-axis diameters were unavailable in imaging reports, though these nodes resolved on imaging after six cycles. Bone lesions were not included in RECIST response evaluation and were interpreted separately on serial bone scans. At cycle 31 (roughly 21 months after toripalimab commencement), PSA stayed undetectable without clinical or radiological signs of progression; the biochemical response persisted for about 19 months starting from cycle 3. As of manuscript revision, the patient remains on toripalimab plus leuprorelin with routine follow-up. No treatment-related adverse events were identified using CTCAE version 5.0. We also conducted a targeted narrative review of mCRPC cases treated with PD-1/PD-L1 inhibitors other than pembrolizumab. This single-case observation highlights the value of genomic profiling for mCRPC patients with relevant biomarkers. Readers should interpret these findings as hypothesis-generating and not proof of universal toripalimab activity.
- Open Access
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (52) , e46439
Case report of fatal myocarditis with toripalimab and axitinib combination therapy
Rationale: Cardiac immune-related adverse events (irAEs) are rare but potentially life-threatening complications of immune checkpoint inhibitor (ICI) therapy, with myocarditis associated with particularly high mortality even under aggressive treatment. Patient concerns: A 65-year-old male with advanced clear cell renal cell carcinoma and liver metastasis presented with progressive wheezing and fatigue following 4 cycles of combination therapy with toripalimab and axitinib, symptoms that failed to respond to conventional supportive measures. Diagnoses: Grade 4 ICI-associated myocarditis was confirmed through a combination of clinical manifestations, characteristic echocardiographic abnormalities, elevated cardiac biomarkers, and the exclusion of infectious causes via comprehensive serological evaluation. Interventions: The patient received multimodal immunosuppressive and supportive therapy, including high-dose methylprednisolone, intravenous immunoglobulin (IVIG), venoarterial extracorporeal membrane oxygenation (VA-ECMO), and therapeutic plasma exchange. Concurrently, broad-spectrum antibiotics were administered based on continuous microbial surveillance. Outcomes: Although transient hemodynamic stabilization was achieved, the patient subsequently developed severe nosocomial infections and progressive multiorgan failure, leading to death on day 24 of hospitalization. Lessons: This case underscores the necessity for early recognition and intensive monitoring in managing high-grade ICI-associated myocarditis. It further highlights the critical role of infection prevention strategies, particularly the implementation of microbial surveillance-guided antibiotic prophylaxis, in patients undergoing combination immunotherapy regimens. Plain Language Summary: We report a 65-year-old male with advanced renal cell carcinoma who developed ICI-associated myocarditis following 4 cycles of combination immunotherapy. The patient presented with progressive dyspnea and fatigue, necessitating hospitalization. Comprehensive diagnostic evaluation confirmed grade 4 myocarditis based on clinical features, elevated cardiac biomarkers, echocardiographic abnormalities, and exclusion of infectious causes. Treatment consisted of multimodal immunosuppressive and life-support therapies, including high-dose methylprednisolone, intravenous IVIG, therapeutic plasma exchange, VA-ECMO, and empiric broad-spectrum antibiotics guided by microbial surveillance. Despite transient hemodynamic stabilization, the patient ultimately progressed to multiorgan failure and died on day 24 of hospitalization. This case underscores the life-threatening nature of ICI-associated myocarditis and highlights the critical need for early recognition, aggressive supportive management, and proactive anti-infective prophylaxis in patients receiving combination immunotherapy.
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104  (52) , e46439
Open AccessCase report of fatal myocarditis with toripalimab and axitinib combination therapy
Rationale: Cardiac immune-related adverse events (irAEs) are rare but potentially life-threatening complications of immune checkpoint inhibitor (ICI) therapy, with myocarditis associated with particularly high mortality even under aggressive treatment. Patient concerns: A 65-year-old male with advanced clear cell renal cell carcinoma and liver metastasis presented with progressive wheezing and fatigue following 4 cycles of combination therapy with toripalimab and axitinib, symptoms that failed to respond to conventional supportive measures. Diagnoses: Grade 4 ICI-associated myocarditis was confirmed through a combination of clinical manifestations, characteristic echocardiographic abnormalities, elevated cardiac biomarkers, and the exclusion of infectious causes via comprehensive serological evaluation. Interventions: The patient received multimodal immunosuppressive and supportive therapy, including high-dose methylprednisolone, intravenous immunoglobulin (IVIG), venoarterial extracorporeal membrane oxygenation (VA-ECMO), and therapeutic plasma exchange. Concurrently, broad-spectrum antibiotics were administered based on continuous microbial surveillance. Outcomes: Although transient hemodynamic stabilization was achieved, the patient subsequently developed severe nosocomial infections and progressive multiorgan failure, leading to death on day 24 of hospitalization. Lessons: This case underscores the necessity for early recognition and intensive monitoring in managing high-grade ICI-associated myocarditis. It further highlights the critical role of infection prevention strategies, particularly the implementation of microbial surveillance-guided antibiotic prophylaxis, in patients undergoing combination immunotherapy regimens. Plain Language Summary: We report a 65-year-old male with advanced renal cell carcinoma who developed ICI-associated myocarditis following 4 cycles of combination immunotherapy. The patient presented with progressive dyspnea and fatigue, necessitating hospitalization. Comprehensive diagnostic evaluation confirmed grade 4 myocarditis based on clinical features, elevated cardiac biomarkers, echocardiographic abnormalities, and exclusion of infectious causes. Treatment consisted of multimodal immunosuppressive and life-support therapies, including high-dose methylprednisolone, intravenous IVIG, therapeutic plasma exchange, VA-ECMO, and empiric broad-spectrum antibiotics guided by microbial surveillance. Despite transient hemodynamic stabilization, the patient ultimately progressed to multiorgan failure and died on day 24 of hospitalization. This case underscores the life-threatening nature of ICI-associated myocarditis and highlights the critical need for early recognition, aggressive supportive management, and proactive anti-infective prophylaxis in patients receiving combination immunotherapy.
- Open Access
- 14 October 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22  (1) , 1-13
Ultra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort
Growing evidence shows that ultra-processed food consumption is associated with the risk of cancer. However, prospective evidence is limited on renal cell carcinoma (RCC) incidence and mortality. In this study, we aimed to examine the association of ultra-processed food consumption and RCC incidence and mortality in a large cohort of US adults. A population-based cohort of 101,688 participants were included from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Ultra-processed food items were confirmed by using the NOVA food classification system. The consumption of ultra-processed food was expressed as a percentage of total food intake (g/day). Prospective associations were calculated using Cox regression. Restricted cubic spline regression was used to assess nonlinearity. Subgroup analyses were performed to investigate the potential effect modifiers on the incidence and mortality of RCC. A total of 410 participants developed RCC during a total of 899,731 person-years of follow-up (median 9.41 years) and 230 RCC deaths during 1,533,930 person-years of follow-up (median 16.85 years). In the fully adjusted model, participants in the highest compared with the lowest quintiles of ultra-processed food consumption had a higher risk of RCC (HR quartile 4 vs 1:1.42; 95% CI: 1.06–1.91; Ptrend = 0.004) and mortality (HR quartile 4 vs. quartile 1: 1.64; 95% CI: 1.10–2.43; Ptrend = 0.027). Linear dose–response associations with RCC incidence and mortality were observed for ultra-processed food consumption (all Pnonlinearity > 0.05). The reliability of these results was supported by sensitivity and subgroup analyses. In conclusion, higher consumption of ultra-processed food is associated with an increased risk of RCC incidence and mortality. Limiting ultra-processed food consumption might be a primary prevention method of RCC.
- 14 October 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22  (1) , 1-13
Open AccessUltra-processed food consumption and renal cell carcinoma incidence and mortality: results from a large prospective cohort
Growing evidence shows that ultra-processed food consumption is associated with the risk of cancer. However, prospective evidence is limited on renal cell carcinoma (RCC) incidence and mortality. In this study, we aimed to examine the association of ultra-processed food consumption and RCC incidence and mortality in a large cohort of US adults. A population-based cohort of 101,688 participants were included from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Ultra-processed food items were confirmed by using the NOVA food classification system. The consumption of ultra-processed food was expressed as a percentage of total food intake (g/day). Prospective associations were calculated using Cox regression. Restricted cubic spline regression was used to assess nonlinearity. Subgroup analyses were performed to investigate the potential effect modifiers on the incidence and mortality of RCC. A total of 410 participants developed RCC during a total of 899,731 person-years of follow-up (median 9.41 years) and 230 RCC deaths during 1,533,930 person-years of follow-up (median 16.85 years). In the fully adjusted model, participants in the highest compared with the lowest quintiles of ultra-processed food consumption had a higher risk of RCC (HR quartile 4 vs 1:1.42; 95% CI: 1.06–1.91; Ptrend = 0.004) and mortality (HR quartile 4 vs. quartile 1: 1.64; 95% CI: 1.10–2.43; Ptrend = 0.027). Linear dose–response associations with RCC incidence and mortality were observed for ultra-processed food consumption (all Pnonlinearity > 0.05). The reliability of these results was supported by sensitivity and subgroup analyses. In conclusion, higher consumption of ultra-processed food is associated with an increased risk of RCC incidence and mortality. Limiting ultra-processed food consumption might be a primary prevention method of RCC.
- Open Access
- 15 September 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8  (1) , 1-13
Integrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response
Tumor ecosystem shapes cancer biology and potentially influence the response to immunotherapy, but there is a lack of direct clinical evidence. In this study, we utilized EcoTyper and publicly available scRNA-Seq cohorts from ICI-treated patients. We found a ecosystem subtype (ecotype) was linked to improved responses to immunotherapy. Then, a novel immunotherapy-responsive ecotype signature (IRE.Sig) was established and validated through the analysis of pan-cancer data. Utilizing IRE.Sig, machine learning models successfully predicted ICI responses in both validation and testing cohorts, achieving area under the curve (AUC) values of 0.72 and 0.71, respectively. Furthermore, using 5 CRISPR screening cohorts, we identified several potential drugs that may augment the efficacy of ICI. We also elucidated the candidate cellular biomarkers of response to the combined treatment of pembrolizumab plus eribulin in breast cancer. This signature has the potential to serve as a valuable tool for patients in selecting appropriate immunotherapy treatments.
- 15 September 2024
- Published by Springer Nature in npj Precision Oncology
- Vol. 8  (1) , 1-13
Open AccessIntegrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response
Tumor ecosystem shapes cancer biology and potentially influence the response to immunotherapy, but there is a lack of direct clinical evidence. In this study, we utilized EcoTyper and publicly available scRNA-Seq cohorts from ICI-treated patients. We found a ecosystem subtype (ecotype) was linked to improved responses to immunotherapy. Then, a novel immunotherapy-responsive ecotype signature (IRE.Sig) was established and validated through the analysis of pan-cancer data. Utilizing IRE.Sig, machine learning models successfully predicted ICI responses in both validation and testing cohorts, achieving area under the curve (AUC) values of 0.72 and 0.71, respectively. Furthermore, using 5 CRISPR screening cohorts, we identified several potential drugs that may augment the efficacy of ICI. We also elucidated the candidate cellular biomarkers of response to the combined treatment of pembrolizumab plus eribulin in breast cancer. This signature has the potential to serve as a valuable tool for patients in selecting appropriate immunotherapy treatments.
- 13 October 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56  (3) , 973-980
Development and validation of a model for predicting the risk of prostate cancer
Background Abnormal hematologic parameters before patients undergoing prostate biopsy play a pivotal role in guiding the surgical management of prostate cancer (PCa) incidence. This study aims to establish the first nomogram for predicting PCa risk for better surgical management. Methods We retrospectively reviewed and analyzed the data including basic information, preoperative hematologic parameters, and imaging examination of 540 consecutive patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsy for elevated prostate-specific antigen (PSA) in our medical center between 2017 and 2021. Logistic regression analysis was used to determine the risk factors for PCa occurrence, and the nomogram was constructed to predict PCa occurrence. Finally, the data including 121 consecutive patients in 2022 were prospectively collected to further verify the results. Results In retrospective analyses, univariate and multivariate logistic analyses identified that three variables including age, diabetes, and De Ritis ratio (aspartate transaminase/alanine transaminase, AST/ALT) were determined to be significantly associated with PCa occurrence. A nomogram was constructed based on these variables for predicting the risk of PCa, and a satisfied predictive accuracy of the model was determined with a C-index of 0.765, supported by a prospective validation group with a C-index of 0.736. The Decision curve analysis showed promising clinical application. In addition, our results also showed that the De Ritis ratio was significantly correlated with the clinical stage of PCa patients, including T, N, and M stages, but insignificantly related to the Gleason score. Conclusions The increased De Ritis ratio was significantly associated with the risk and clinical stage of PCa and this nomogram with good discrimination could effectively improve individualized surgical management for patient underdoing prostate biopsy.
- 13 October 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56  (3) , 973-980
Development and validation of a model for predicting the risk of prostate cancer
Background Abnormal hematologic parameters before patients undergoing prostate biopsy play a pivotal role in guiding the surgical management of prostate cancer (PCa) incidence. This study aims to establish the first nomogram for predicting PCa risk for better surgical management. Methods We retrospectively reviewed and analyzed the data including basic information, preoperative hematologic parameters, and imaging examination of 540 consecutive patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsy for elevated prostate-specific antigen (PSA) in our medical center between 2017 and 2021. Logistic regression analysis was used to determine the risk factors for PCa occurrence, and the nomogram was constructed to predict PCa occurrence. Finally, the data including 121 consecutive patients in 2022 were prospectively collected to further verify the results. Results In retrospective analyses, univariate and multivariate logistic analyses identified that three variables including age, diabetes, and De Ritis ratio (aspartate transaminase/alanine transaminase, AST/ALT) were determined to be significantly associated with PCa occurrence. A nomogram was constructed based on these variables for predicting the risk of PCa, and a satisfied predictive accuracy of the model was determined with a C-index of 0.765, supported by a prospective validation group with a C-index of 0.736. The Decision curve analysis showed promising clinical application. In addition, our results also showed that the De Ritis ratio was significantly correlated with the clinical stage of PCa patients, including T, N, and M stages, but insignificantly related to the Gleason score. Conclusions The increased De Ritis ratio was significantly associated with the risk and clinical stage of PCa and this nomogram with good discrimination could effectively improve individualized surgical management for patient underdoing prostate biopsy.
- Open Access
- 24 August 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23  (1) , 1-14
Pan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
The association between specific genetic mutations and immunotherapy benefits has been widely known, while such studies in pan-cancer are still limited. SPEN, mainly involved in X chromosome inactivation (XCI), plays an essential in tumorigenesis and sex differences in cancer. Thus, we firstly analyzed the potential role of SPEN in the TCGA pan-cancer cohort and clinical samples. Bioinformatics analysis and immunohistochemistry (IHC) staining confirm that the expression of SPEN is significantly different in various cancers and may involve RNA splicing and processing via enrichment analysis. Then, our data further revealed that those patients with SPEN mutation could predict a better prognosis in pan-cancer and had distinct immune signatures, higher tumor mutation burden (TMB), and microsatellite instability (MSI) in common cancer types. Finally, the cancer patients from 9 studies treated with immune checkpoint inhibitors were included to investigate the efficacy of immunotherapy. The results further showed that SPEN mutation was associated with better clinical outcomes (HR, 0.74; 95%CI, 0.59–0.93, P = 0.01), and this association remained existed in female patients (HR, 0.60; 95%CI, 0.38–0.94 P = 0.024), but not in male patients (HR, 0.82; 95%CI, 0.62–1.08 P = 0.150). Our findings demonstrated that SPEN mutation might strongly predict immunotherapy efficacy in pan-cancer.
- 24 August 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23  (1) , 1-14
Open AccessPan-cancer analysis identifies SPEN mutation as a predictive biomarker with the efficacy of immunotherapy
The association between specific genetic mutations and immunotherapy benefits has been widely known, while such studies in pan-cancer are still limited. SPEN, mainly involved in X chromosome inactivation (XCI), plays an essential in tumorigenesis and sex differences in cancer. Thus, we firstly analyzed the potential role of SPEN in the TCGA pan-cancer cohort and clinical samples. Bioinformatics analysis and immunohistochemistry (IHC) staining confirm that the expression of SPEN is significantly different in various cancers and may involve RNA splicing and processing via enrichment analysis. Then, our data further revealed that those patients with SPEN mutation could predict a better prognosis in pan-cancer and had distinct immune signatures, higher tumor mutation burden (TMB), and microsatellite instability (MSI) in common cancer types. Finally, the cancer patients from 9 studies treated with immune checkpoint inhibitors were included to investigate the efficacy of immunotherapy. The results further showed that SPEN mutation was associated with better clinical outcomes (HR, 0.74; 95%CI, 0.59–0.93, P = 0.01), and this association remained existed in female patients (HR, 0.60; 95%CI, 0.38–0.94 P = 0.024), but not in male patients (HR, 0.82; 95%CI, 0.62–1.08 P = 0.150). Our findings demonstrated that SPEN mutation might strongly predict immunotherapy efficacy in pan-cancer.
- Open Access
- 6 June 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1138386
Single-cell multi-omics analysis reveals dysfunctional Wnt signaling of spermatogonia in non-obstructive azoospermia
Background: Non-obstructive azoospermia (NOA) is the most severe type that leads to 1% of male infertility. Wnt signaling governs normal sperm maturation. However, the role of Wnt signaling in spermatogonia in NOA has incompletely been uncovered, and upstream molecules regulating Wnt signaling remain unclear.Methods: Bulk RNA sequencing (RNA-seq) of NOA was used to identify the hub gene module in NOA utilizing weighted gene co-expression network analyses (WGCNAs). Single-cell RNA sequencing (scRNA-seq) of NOA was employed to explore dysfunctional signaling pathways in the specific cell type with gene sets of signaling pathways. Single-cell regulatory network inference and clustering (pySCENIC) for Python analysis was applied to speculate putative transcription factors in spermatogonia. Moreover, single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) determined the regulated genes of these transcription factors. Finally, spatial transcriptomic data were used to analyze cell type and Wnt signaling spatial distribution.Results: The Wnt signaling pathway was demonstrated to be enriched in the hub gene module of NOA by bulk RNA-seq. Then, scRNA-seq data revealed the downregulated activity and dysfunction of Wnt signaling of spermatogonia in NOA samples. Conjoint analyses of the pySCENIC algorithm and scATAC-seq data indicated that three transcription factors (CTCF, AR, and ARNTL) were related to the activities of Wnt signaling in NOA. Eventually, spatial expression localization of Wnt signaling was identified to be in accordance with the distribution patterns of spermatogonia, Sertoli cells, and Leydig cells.Conclusion: In conclusion, we identified that downregulated Wnt signaling of spermatogonia in NOA and three transcription factors (CTCF, AR, and ARNTL) may be involved in this dysfunctional Wnt signaling. These findings provide new mechanisms for NOA and new therapeutic targets for NOA patients.
- 6 June 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1138386
Open AccessSingle-cell multi-omics analysis reveals dysfunctional Wnt signaling of spermatogonia in non-obstructive azoospermia
Background: Non-obstructive azoospermia (NOA) is the most severe type that leads to 1% of male infertility. Wnt signaling governs normal sperm maturation. However, the role of Wnt signaling in spermatogonia in NOA has incompletely been uncovered, and upstream molecules regulating Wnt signaling remain unclear.Methods: Bulk RNA sequencing (RNA-seq) of NOA was used to identify the hub gene module in NOA utilizing weighted gene co-expression network analyses (WGCNAs). Single-cell RNA sequencing (scRNA-seq) of NOA was employed to explore dysfunctional signaling pathways in the specific cell type with gene sets of signaling pathways. Single-cell regulatory network inference and clustering (pySCENIC) for Python analysis was applied to speculate putative transcription factors in spermatogonia. Moreover, single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) determined the regulated genes of these transcription factors. Finally, spatial transcriptomic data were used to analyze cell type and Wnt signaling spatial distribution.Results: The Wnt signaling pathway was demonstrated to be enriched in the hub gene module of NOA by bulk RNA-seq. Then, scRNA-seq data revealed the downregulated activity and dysfunction of Wnt signaling of spermatogonia in NOA samples. Conjoint analyses of the pySCENIC algorithm and scATAC-seq data indicated that three transcription factors (CTCF, AR, and ARNTL) were related to the activities of Wnt signaling in NOA. Eventually, spatial expression localization of Wnt signaling was identified to be in accordance with the distribution patterns of spermatogonia, Sertoli cells, and Leydig cells.Conclusion: In conclusion, we identified that downregulated Wnt signaling of spermatogonia in NOA and three transcription factors (CTCF, AR, and ARNTL) may be involved in this dysfunctional Wnt signaling. These findings provide new mechanisms for NOA and new therapeutic targets for NOA patients.
- Open Access
- 7 April 2023
- Published by Springer Nature in Research Square
Nutritional status as the risk factor of urosepsis in patients with benign prostatic hyperplasia
Objectives This study aimed to investigate the risk factors associated with urosepsis in patients with benign prostatic hyperplasia (BPH), particularly focusing on nutritional status. Methods We retrospectively analyzed data from 65 BPH patients admitted to our hospital between January 2020 and November 2022 for urosepsis. We also matched 130 BPH patients without urinary tract infection (UTI) as controls with a matching ratio of 1:2. Nutritional status was assessed according to the prognostic nutritional index (PNI) score, the controlling nutrition status (CONUT) score, and the Naples prognostic score (NPS). Results Compared with BPH patients without UTI, patients with urosepsis had significantly lower BMI (21.76 ± 2.99 vs. 23.60 ± 3.09, P<0.001) and PNI score (38.56 ± 7.03 vs. 45.45 ± 5.11, P = 0.003), and higher CONUT score (5.47 ± 2.71 vs. 2.17 ± 1.73, P<0.001) and NPS (3.55 ± 0.79 vs. 2.35 ± 1.15, P<0.001). Logistic regression analysis showed that the CONUT score, the NPS, serum albumin, and height were independent and significant risk factors for urosepsis in patients with BPH. Conclusion Poor nutritional status may increase the risk of urosepsis in patients with BPH. Therefore, the improvement of nutritional status is conducive to the prevention of severe UTIs in elderly men with BPH.
- 7 April 2023
- Published by Springer Nature in Research Square
Open AccessNutritional status as the risk factor of urosepsis in patients with benign prostatic hyperplasia
Objectives This study aimed to investigate the risk factors associated with urosepsis in patients with benign prostatic hyperplasia (BPH), particularly focusing on nutritional status. Methods We retrospectively analyzed data from 65 BPH patients admitted to our hospital between January 2020 and November 2022 for urosepsis. We also matched 130 BPH patients without urinary tract infection (UTI) as controls with a matching ratio of 1:2. Nutritional status was assessed according to the prognostic nutritional index (PNI) score, the controlling nutrition status (CONUT) score, and the Naples prognostic score (NPS). Results Compared with BPH patients without UTI, patients with urosepsis had significantly lower BMI (21.76 ± 2.99 vs. 23.60 ± 3.09, P<0.001) and PNI score (38.56 ± 7.03 vs. 45.45 ± 5.11, P = 0.003), and higher CONUT score (5.47 ± 2.71 vs. 2.17 ± 1.73, P<0.001) and NPS (3.55 ± 0.79 vs. 2.35 ± 1.15, P<0.001). Logistic regression analysis showed that the CONUT score, the NPS, serum albumin, and height were independent and significant risk factors for urosepsis in patients with BPH. Conclusion Poor nutritional status may increase the risk of urosepsis in patients with BPH. Therefore, the improvement of nutritional status is conducive to the prevention of severe UTIs in elderly men with BPH.
- Open Access
- 1 March 2023
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 12  (3) , 455-+
Research of targeted therapy for renal cancer from 2006 to 2022 a bibliometric and visualized analysis
Background: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022.Methods: The Web of Science Core Collection database was searched using the search terms "renal cancer", "kidney neoplasms", "kidney cancer", and "targeted therapy", and all publications were extracted. VOSviewer version 1.6.18 was used to complete the visual analysis based on the information of publications, including author, journal, subject, year, and institution.Results: A total of 1,136 studies related to TT for RC were found. The top journals in this field were the Journal of Clinical Oncology, Annals of Oncology, and European Urology. Among them, the Journal of Clinical Oncology had the highest number of publications (n=35). In terms of country, the United States had the highest number of publications (n=366). The main document type was article, which accounted for 64.26% of the total publications.Conclusions: To the best of our knowledge, this is the first bibliometric analysis related to TT for RC. The annual number of publications has exhibited a steady growth trend, with the United States having the greatest contribution in this field. Through an analysis of a keyword time density map, we identified that hypoxia-inducing factor-1, drug resistance and therapeutic targets are the research hotspots and trends in this field.
- 1 March 2023
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 12  (3) , 455-+
Open AccessResearch of targeted therapy for renal cancer from 2006 to 2022 a bibliometric and visualized analysis
Background: This review aimed to analyze the research progress and development trends in targeted therapy (TT) for renal cancer (RC) from 2006 to 2022.Methods: The Web of Science Core Collection database was searched using the search terms "renal cancer", "kidney neoplasms", "kidney cancer", and "targeted therapy", and all publications were extracted. VOSviewer version 1.6.18 was used to complete the visual analysis based on the information of publications, including author, journal, subject, year, and institution.Results: A total of 1,136 studies related to TT for RC were found. The top journals in this field were the Journal of Clinical Oncology, Annals of Oncology, and European Urology. Among them, the Journal of Clinical Oncology had the highest number of publications (n=35). In terms of country, the United States had the highest number of publications (n=366). The main document type was article, which accounted for 64.26% of the total publications.Conclusions: To the best of our knowledge, this is the first bibliometric analysis related to TT for RC. The annual number of publications has exhibited a steady growth trend, with the United States having the greatest contribution in this field. Through an analysis of a keyword time density map, we identified that hypoxia-inducing factor-1, drug resistance and therapeutic targets are the research hotspots and trends in this field.
- Open Access
- 28 October 2022
- Published by Springer Nature in Research Square
Sex differences in the association between the effect of bariatric surgery and cancer risk: A meta-analysis including 18 million individuals
Background Studies have suggested an association between bariatric surgery for obesity with cancer risk. Whether the effect of bariatric surgery could reduce the same excess risk of overall cancer in women and men is unknown. Methods PubMed, EMBASE, and Web of Science were searched to identify cohort studies up to 15 September 2022. Included studies reported the association between bariatric surgery for obesity and cancer risk in men and/or female. Random-effects meta-analyses weighted by the inverse of the variances were applied to pool sex-specific RRs and women-to-men ratios of RRs (RRRs) for overall cancer risk. Results 18 studies involved with 18,603,812 patients (18,028,898 controls and 573,914 bariatric patients) met the inclusion criteria and were eligible for analysis. The results showed that bariatric surgery was significantly associated with decreased overall cancer risk (RR = 0.68, 95% CI 0.60, 0.78; P < 0.001) in women, but not associated with overall cancer risk (RR = 0.94, 95% CI 0.79, 1.12; P = 0.470) in men. The pooled women-to-men RRR showed an 18% lower reduction of overall cancer associated with bariatric surgery in women than in men (RRR = 0.82, 95% CI 0.75–0.90; P < 0.001). The pooled women-to-men RRR showed an 18% lower reduction of overall cancer associated with bariatric surgery in women than in men RRR = 0.82, 95% CI 0.74–0.92; P < 0.001). Conclusion The effect of bariatric surgery is significantly associated with a lower reduction of cancer for women compared to men.
- 28 October 2022
- Published by Springer Nature in Research Square
Open AccessSex differences in the association between the effect of bariatric surgery and cancer risk: A meta-analysis including 18 million individuals
Background Studies have suggested an association between bariatric surgery for obesity with cancer risk. Whether the effect of bariatric surgery could reduce the same excess risk of overall cancer in women and men is unknown. Methods PubMed, EMBASE, and Web of Science were searched to identify cohort studies up to 15 September 2022. Included studies reported the association between bariatric surgery for obesity and cancer risk in men and/or female. Random-effects meta-analyses weighted by the inverse of the variances were applied to pool sex-specific RRs and women-to-men ratios of RRs (RRRs) for overall cancer risk. Results 18 studies involved with 18,603,812 patients (18,028,898 controls and 573,914 bariatric patients) met the inclusion criteria and were eligible for analysis. The results showed that bariatric surgery was significantly associated with decreased overall cancer risk (RR = 0.68, 95% CI 0.60, 0.78; P < 0.001) in women, but not associated with overall cancer risk (RR = 0.94, 95% CI 0.79, 1.12; P = 0.470) in men. The pooled women-to-men RRR showed an 18% lower reduction of overall cancer associated with bariatric surgery in women than in men (RRR = 0.82, 95% CI 0.75–0.90; P < 0.001). The pooled women-to-men RRR showed an 18% lower reduction of overall cancer associated with bariatric surgery in women than in men RRR = 0.82, 95% CI 0.74–0.92; P < 0.001). Conclusion The effect of bariatric surgery is significantly associated with a lower reduction of cancer for women compared to men.